Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hasun, M; Dörler, J; Edlinger, M; Alber, H; Von Lewinski, D; Eber, B; Roithinger, FX; Berger, R; Siostrzonek, P; Grimm, G; Benzer, W; Wintersteller, W; Huber, K; Schuchlenz, H; Weidinger, F; Austrian Acute PCI Investigators.
In-Hospital Outcome Comparing Bivalirudin to Heparin in Real-World Primary Percutaneous Coronary Intervention.
Am J Cardiol. 2017; 120(12):2135-2140
Doi: 10.1016/j.amjcard.2017.08.037
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- von Lewinski Dirk
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Randomized controlled trials have shown conflicting results regarding the outcome of bivalirudin in primary percutaneous coronary intervention (PPCI). The aim of this study was to evaluate the in-hospital outcomes of patients receiving heparin or bivalirudin in a real-world setting of PPCI: 7,023 consecutive patients enrolled in the Austrian Acute PCI Registry were included between January 2010 and December 2014. Patients were classified according to the peri-interventional anticoagulation regimen receiving heparin (n = 6430) or bivalirudin (n = 593) with or without GpIIb/IIIa inhibitors (GPIs). In-hospital mortality (odds ratio [OR] 1.13, 95% confidence interval [CI] 0.57 to 2.25, p = 0.72), major adverse cardiovascular events (OR 1.18, 95% CI 0.65 to 2.14, p = 0.59), net adverse clinical events (OR 1.01, 95% CI 0.57 to 1.77, p = 0.99), and TIMI non-coronary artery bypass graft-related major bleeding (OR 0.41, 95% CI 0.09 to 1.86, p = 0.25) were not significantly different between the groups. However, we detected potential effect modifications of anticoagulants on mortality by GPIs (OR 0.12, 95% CI 0.01 to 1.07, p = 0.06) and access site (OR 0.25, 95% CI 0.06 to 1.03, p = 0.06) favoring bivalirudin in femoral access. In conclusion, this large real-world cohort of PPCI, heparin-based anticoagulation showed similar results of short-term mortality compared with bivalirudin. We observed a potential effect modification by additional GPI use and access favoring bivalirudin over heparin in femoral, but not radial, access. Copyright © 2017 Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Antithrombins - administration & dosage
- Austria - epidemiology
- Dose-Response Relationship, Drug -
- Female -
- Fibrinolytic Agents -
- Follow-Up Studies -
- Heparin - administration & dosage
- Hirudins - administration & dosage
- Hospital Mortality - trends
- Humans -
- Inpatients -
- Male -
- Middle Aged -
- Myocardial Infarction - mortality
- Myocardial Infarction - therapy
- Odds Ratio -
- Peptide Fragments - administration & dosage
- Percutaneous Coronary Intervention - methods
- Prospective Studies -
- Recombinant Proteins - administration & dosage
- Registries -
- Survival Rate - trends
- Treatment Outcome -